Table 4.
Baseline descriptive statistics of the treatment subgroups with liver T2* value < 9.2 ms
| P | Deferiprone group (n = 23) | Combined group (n = 41) | Deferoxamine group (n =33) | P | |
|---|---|---|---|---|---|
|
Age (yrs) |
0.376 |
30.6 ± 6.1 |
28.9 ± 6.2 |
30.3 ± 8.3 |
0.439 |
|
Male (%) |
0.108 |
69.6% |
48.8% |
51.5% |
0.815 |
|
Chel. starting age (yrs) |
0.548 |
5.1 ± 5.7 |
4.2 ± 4.3 |
5.4 ± 3.9 |
0.326 |
|
Ferritin (ng/l) |
<0.0001 |
1347 ± 1782 |
2101 ± 944 |
1729 ± 1672 |
0.009 |
|
Liver T2* (ms) |
0.733 |
3.3 ± 2.1 |
3.6 ± 2.3 |
4.0 ± 2.0 |
0.272 |
| MRI LIC (mg/g dry weight) | 0.940 | 12.5 ± 9.5 | 12.3 ± 10.2 | 9.6 ± 7.2 | 0.197 |
All values are quoted as mean ± SD.